Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endocarditis | 5 | 2020 | 22 | 1.780 |
Why?
|
| Prosthesis-Related Infections | 7 | 2019 | 31 | 1.240 |
Why?
|
| Pacemaker, Artificial | 7 | 2019 | 40 | 1.200 |
Why?
|
| Defibrillators, Implantable | 7 | 2019 | 44 | 1.200 |
Why?
|
| Endocarditis, Bacterial | 5 | 2020 | 15 | 0.950 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2020 | 58 | 0.660 |
Why?
|
| Pulmonary Valve | 1 | 2020 | 12 | 0.640 |
Why?
|
| Drug Users | 1 | 2020 | 15 | 0.620 |
Why?
|
| Injections | 1 | 2020 | 72 | 0.610 |
Why?
|
| Intracranial Hemorrhages | 1 | 2019 | 34 | 0.600 |
Why?
|
| Opportunistic Infections | 2 | 2017 | 19 | 0.560 |
Why?
|
| Anticoagulants | 1 | 2019 | 122 | 0.550 |
Why?
|
| Stroke | 2 | 2019 | 691 | 0.530 |
Why?
|
| Salvage Therapy | 1 | 2018 | 135 | 0.520 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 8 | 0.520 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2017 | 7 | 0.510 |
Why?
|
| Antirheumatic Agents | 1 | 2017 | 28 | 0.510 |
Why?
|
| Hospitalization | 1 | 2020 | 475 | 0.500 |
Why?
|
| Staphylococcal Infections | 4 | 2005 | 78 | 0.490 |
Why?
|
| Neutropenia | 2 | 2009 | 24 | 0.490 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 248 | 0.460 |
Why?
|
| Drug Therapy, Combination | 4 | 2005 | 292 | 0.440 |
Why?
|
| Staphylococcus aureus | 4 | 2005 | 55 | 0.430 |
Why?
|
| Device Removal | 4 | 2018 | 39 | 0.410 |
Why?
|
| Aged | 16 | 2020 | 10256 | 0.380 |
Why?
|
| Virginiamycin | 2 | 2003 | 3 | 0.370 |
Why?
|
| Male | 19 | 2020 | 19443 | 0.350 |
Why?
|
| Humans | 25 | 2020 | 32278 | 0.340 |
Why?
|
| Fusobacterium Infections | 1 | 2011 | 2 | 0.340 |
Why?
|
| Fusobacterium necrophorum | 1 | 2011 | 2 | 0.340 |
Why?
|
| Female | 20 | 2020 | 19949 | 0.330 |
Why?
|
| Enterococcus | 2 | 2019 | 13 | 0.330 |
Why?
|
| Antifungal Agents | 2 | 2010 | 44 | 0.320 |
Why?
|
| Middle Aged | 17 | 2020 | 11844 | 0.300 |
Why?
|
| Geotrichosis | 1 | 2009 | 2 | 0.300 |
Why?
|
| Geotrichum | 1 | 2009 | 2 | 0.300 |
Why?
|
| Echinocandins | 1 | 2009 | 7 | 0.300 |
Why?
|
| Lipopeptides | 1 | 2009 | 7 | 0.300 |
Why?
|
| Retrospective Studies | 5 | 2020 | 3610 | 0.240 |
Why?
|
| Adult | 8 | 2020 | 9258 | 0.240 |
Why?
|
| North Carolina | 2 | 2020 | 1300 | 0.230 |
Why?
|
| Prospective Studies | 9 | 2019 | 2317 | 0.230 |
Why?
|
| Spinal Diseases | 1 | 2005 | 21 | 0.230 |
Why?
|
| Osteomyelitis | 1 | 2005 | 26 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 6 | 2019 | 324 | 0.220 |
Why?
|
| Streptococcal Infections | 1 | 2004 | 23 | 0.210 |
Why?
|
| Streptococcus pneumoniae | 1 | 2004 | 38 | 0.210 |
Why?
|
| Arthritis, Infectious | 1 | 2004 | 25 | 0.210 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2003 | 24 | 0.190 |
Why?
|
| Oxacillin | 1 | 2003 | 5 | 0.190 |
Why?
|
| Vancomycin | 1 | 2003 | 16 | 0.190 |
Why?
|
| Tobramycin | 1 | 2002 | 1 | 0.190 |
Why?
|
| Piperacillin | 1 | 2002 | 5 | 0.190 |
Why?
|
| Ciprofloxacin | 1 | 2002 | 13 | 0.180 |
Why?
|
| Risk Factors | 5 | 2018 | 3936 | 0.180 |
Why?
|
| Fever | 1 | 2002 | 60 | 0.180 |
Why?
|
| Ventriculostomy | 1 | 2002 | 10 | 0.180 |
Why?
|
| Meningitis, Bacterial | 1 | 2002 | 6 | 0.180 |
Why?
|
| Vancomycin Resistance | 1 | 2002 | 9 | 0.180 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 3898 | 0.180 |
Why?
|
| Hospitals, Teaching | 2 | 2020 | 28 | 0.170 |
Why?
|
| Registries | 3 | 2018 | 294 | 0.170 |
Why?
|
| Intracranial Embolism | 1 | 2020 | 15 | 0.160 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2020 | 34 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2020 | 1840 | 0.160 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2019 | 13 | 0.150 |
Why?
|
| Bacteremia | 3 | 2005 | 66 | 0.150 |
Why?
|
| Treatment Failure | 1 | 2018 | 164 | 0.130 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 50 | 0.130 |
Why?
|
| Rheumatology | 1 | 2017 | 10 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2017 | 3407 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 100 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2019 | 818 | 0.100 |
Why?
|
| Dapsone | 1 | 2014 | 5 | 0.100 |
Why?
|
| Anemia, Hemolytic | 1 | 2014 | 8 | 0.100 |
Why?
|
| Electrodes, Implanted | 1 | 2014 | 54 | 0.100 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 21 | 0.100 |
Why?
|
| Young Adult | 1 | 2020 | 2651 | 0.100 |
Why?
|
| Anxiety | 1 | 2014 | 195 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2014 | 158 | 0.090 |
Why?
|
| Ethnic Groups | 1 | 2014 | 450 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2009 | 78 | 0.090 |
Why?
|
| Depression | 1 | 2014 | 427 | 0.080 |
Why?
|
| Lung Abscess | 1 | 2011 | 1 | 0.080 |
Why?
|
| Jugular Veins | 1 | 2011 | 24 | 0.080 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2010 | 2 | 0.080 |
Why?
|
| Methicillin Resistance | 3 | 2005 | 24 | 0.080 |
Why?
|
| Cryptococcosis | 1 | 2010 | 7 | 0.080 |
Why?
|
| Immunocompetence | 1 | 2010 | 12 | 0.080 |
Why?
|
| Thrombosis | 1 | 2011 | 78 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 53 | 0.080 |
Why?
|
| Electrocardiography | 1 | 2014 | 624 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2009 | 85 | 0.070 |
Why?
|
| Sepsis | 1 | 2011 | 164 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2014 | 826 | 0.070 |
Why?
|
| Infusions, Intravenous | 2 | 2012 | 97 | 0.070 |
Why?
|
| Blood Sedimentation | 1 | 2005 | 5 | 0.060 |
Why?
|
| Leukocytosis | 1 | 2005 | 8 | 0.060 |
Why?
|
| Infusions, Parenteral | 1 | 2005 | 63 | 0.060 |
Why?
|
| Debridement | 1 | 2005 | 45 | 0.060 |
Why?
|
| Abscess | 1 | 2005 | 28 | 0.060 |
Why?
|
| Drainage | 1 | 2005 | 65 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2005 | 200 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2005 | 267 | 0.050 |
Why?
|
| Penicillin Resistance | 1 | 2003 | 1 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2005 | 275 | 0.050 |
Why?
|
| Penicillins | 1 | 2002 | 12 | 0.050 |
Why?
|
| Leukemia | 1 | 2002 | 38 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2002 | 35 | 0.050 |
Why?
|
| Lymphoma | 1 | 2002 | 37 | 0.050 |
Why?
|
| Injections, Intraventricular | 1 | 2002 | 16 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2002 | 68 | 0.040 |
Why?
|
| United States | 3 | 2017 | 4074 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2005 | 534 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2002 | 567 | 0.040 |
Why?
|
| Recurrence | 2 | 2017 | 286 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 2238 | 0.040 |
Why?
|
| Time Factors | 2 | 2014 | 2203 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 47 | 0.030 |
Why?
|
| Cardiovascular Infections | 1 | 2017 | 1 | 0.030 |
Why?
|
| Electrophysiological Phenomena | 1 | 2017 | 29 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 42 | 0.030 |
Why?
|
| Incidence | 2 | 2014 | 1242 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 321 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 367 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 1212 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2003 | 128 | 0.020 |
Why?
|
| Chi-Square Distribution | 2 | 2003 | 287 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2014 | 197 | 0.020 |
Why?
|
| Survival Rate | 1 | 2014 | 892 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 955 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 1423 | 0.020 |
Why?
|
| Cryptococcus | 1 | 2010 | 1 | 0.020 |
Why?
|
| Taiwan | 1 | 2010 | 11 | 0.020 |
Why?
|
| APACHE | 1 | 2010 | 13 | 0.020 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2010 | 8 | 0.020 |
Why?
|
| Australia | 1 | 2010 | 35 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2010 | 34 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 476 | 0.020 |
Why?
|
| Prognosis | 1 | 2010 | 1529 | 0.010 |
Why?
|
| HIV Infections | 1 | 2010 | 450 | 0.010 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2003 | 12 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2003 | 273 | 0.010 |
Why?
|
| Logistic Models | 1 | 2003 | 743 | 0.010 |
Why?
|
| Adolescent | 1 | 2003 | 3516 | 0.010 |
Why?
|